Abstract
MicroRNAs are a major category among the noncoding RNA fraction that negatively regulate gene expression at the post-transcriptional level, by either degrading the target messages or inhibiting their translation. MicroRNAs may be referred to as ‘dimmer switches’ of gene expression, because of their ability to repress gene expression without completely silencing it. Whether through up-regulating specific groups of microRNAs to suppress unwanted gene expressions, or by down-regulating other microRNAs whose target genes expression is necessary for cellular function, such as cell proliferation, apoptosis, or differentiation, these regulatory RNAs play pivotal roles in a wide variety of cellular processes. The equilibrium between these two groups of microRNA expressions largely determines the function of particular cell types. Our recent results with several model systems show that upon aging, there is a trend of up-regulation of microRNA expression, with concomitant inverse down-regulation of target genes. This review addresses molecular mechanisms that may provide the underlying control for this up-regulating trend, focusing on activation by various microRNAs own promoters, through binding with pivotal transcription factors, stress response, methylation of clustered DNA domains, etc. Thus, epigenomic control of aging may be due in part to heightened promoter activation of unwanted microRNA expressions, which in turn down-regulate their target gene products. Overriding and dampening the activation of these noncoding RNAs may prove to be a new frontier for future research, to delay aging and extend healthy life-span.
Keywords: MicroRNA, promoter, transcription factor, transcription factor binding site
Current Genomics
Title: Epigenetic Control of MicroRNA Expression and Aging
Volume: 10 Issue: 3
Author(s): Ruqiang Liang, David J. Bates and Eugenia Wang
Affiliation:
Keywords: MicroRNA, promoter, transcription factor, transcription factor binding site
Abstract: MicroRNAs are a major category among the noncoding RNA fraction that negatively regulate gene expression at the post-transcriptional level, by either degrading the target messages or inhibiting their translation. MicroRNAs may be referred to as ‘dimmer switches’ of gene expression, because of their ability to repress gene expression without completely silencing it. Whether through up-regulating specific groups of microRNAs to suppress unwanted gene expressions, or by down-regulating other microRNAs whose target genes expression is necessary for cellular function, such as cell proliferation, apoptosis, or differentiation, these regulatory RNAs play pivotal roles in a wide variety of cellular processes. The equilibrium between these two groups of microRNA expressions largely determines the function of particular cell types. Our recent results with several model systems show that upon aging, there is a trend of up-regulation of microRNA expression, with concomitant inverse down-regulation of target genes. This review addresses molecular mechanisms that may provide the underlying control for this up-regulating trend, focusing on activation by various microRNAs own promoters, through binding with pivotal transcription factors, stress response, methylation of clustered DNA domains, etc. Thus, epigenomic control of aging may be due in part to heightened promoter activation of unwanted microRNA expressions, which in turn down-regulate their target gene products. Overriding and dampening the activation of these noncoding RNAs may prove to be a new frontier for future research, to delay aging and extend healthy life-span.
Export Options
About this article
Cite this article as:
Liang Ruqiang, Bates J. David and Wang Eugenia, Epigenetic Control of MicroRNA Expression and Aging, Current Genomics 2009; 10 (3) . https://dx.doi.org/10.2174/138920209788185225
DOI https://dx.doi.org/10.2174/138920209788185225 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Chronic Kidney Disease Development and Renin-angiotensin System Inhibition on Cardiovascular Prognosis
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Old and New Drugs for Treatment of Stable Angina: New Anti-Anginal Drugs and Coronary Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers
Current Pharmaceutical Design Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment
Current Medicinal Chemistry The Novel Functions of cGMP-Specific Phosphodiesterase 5 and its Inhibitors in Carcinoma Cells and Pulmonary/Cardiovascular Vessels
Current Topics in Medicinal Chemistry Hesperidin Potentiates Ghrelin Signaling
Recent Patents on Food, Nutrition & Agriculture Inflammatory Markers Associated With Diabetes Mellitus – Old and New Players
Current Pharmaceutical Design Acute Fulminant Hepatatis in Kidney Transplant Recipient After Repeated Sevoflurane Anesthesia - A Case Report and Literature Review
Current Drug Safety Self Managing Heart Failure in Remote Australia - Translating Concepts into Clinical Practice
Current Cardiology Reviews Analytical Methods for the Determination of Anti-diuretic Peptides in Biological Samples: Challenges and Perspectives
Current Analytical Chemistry Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Dyspnea in Cancer Patients: A Well-Known and Neglected Symptom
Reviews on Recent Clinical Trials Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Selective Histone Deacetylase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Fontan Circulation Might be Associated with Peripartum Cardiomyopathy: A Review of Mechanistic and Clinical Aspects
Current Cardiology Reviews Editorial (Thematic Issue: Pharmacologic Strategies with Afterload Reduction in Low Cardiac Output Syndrome After Pediatric Cardiac Surgery)
Current Vascular Pharmacology